Shaji Kumar on Later Lines of Treatment for Myeloma
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Read More
Shaji Kumar on Treatment-Related Adverse Events From Monoclonal Antibodies
Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, discusses common treatment-related adverse events from monoclonal antibodies in patients with multiple myeloma.